Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall
Standex International Corp stock reached an all-time high of 215.99 USD, marking a significant milestone for the company. According to InvestingPro data, the stock has delivered an impressive 30% return over the past six months, with a market capitalization of $2.6 billion. This achievement highlights the stock’s robust performance over the past year, during which it has seen a notable increase of 21.05%. The company’s consistent growth and strategic initiatives have contributed to this upward trajectory, reflecting investor confidence and market optimism. The company maintains strong financial health with a current ratio of 2.88 and has maintained dividend payments for 55 consecutive years. Based on InvestingPro’s Fair Value analysis, the stock appears to be trading above its intrinsic value. As Standex continues to innovate and expand its market presence, stakeholders are closely monitoring its next moves in the competitive landscape. With a gross profit margin of 39.9% and revenue growth of 9.64%, the company demonstrates solid operational performance. Discover 8 more exclusive InvestingPro Tips and comprehensive analysis in the Pro Research Report, available on InvestingPro.
In other recent news, Standex International Corporation reported impressive financial results for the fourth quarter of 2025. The company exceeded market expectations with an earnings per share (EPS) of $2.28, surpassing the forecast of $2.10. Revenue also outperformed projections, reaching $222 million compared to the anticipated $214.44 million. Following these strong results, Roth/MKM raised its price target for Standex to $205 from $175, maintaining a Buy rating. The firm highlighted the company’s 23% year-over-year sales growth and an increase in adjusted EBITDA margins by 350 basis points. Similarly, DA Davidson increased its price target to $219 from $200, also maintaining a Buy rating. DA Davidson noted Standex’s potential to reverse a nearly two-year trend of quarterly organic revenue declines. These developments underscore the positive sentiment among analysts regarding Standex’s financial performance and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.